Resveratrol functionalization of a collagen-based scaffold derived from amniotic membrane restores angiogenic activity and tissue regeneration in type 2 diabetic wound repair.

Chronic diabetic wounds remain a major clinical challenge due to persistent inflammation, impaired angiogenesis, excessive oxidative stress, and defective tissue remodeling. The present study aimed to develop and evaluate a bioactive scaffold based on a decellularized amniotic membrane-derived collagen matrix (ColAM) functionalized with resveratrol for enhancing wound healing in a type 2 diabetic model. Diabetic animals were divided into four groups (control, ColAM, resveratrol, and ColAM+Resveratrol), and wound healing was assessed at days 7 and 14 using a full-thickness excisional wound model. Quantitative analysis demonstrated significantly enhanced wound closure in all treated groups compared to control. At day 7, wound closure rates were 27.35 ± 1.87% (control), 37.6 ± 4.21% (ColAM), 35.14 ± 2.39% (resveratrol), and 47.32 ± 5.55% (ColAM+Resveratrol). At day 14, values increased to 46.43 ± 4.98%, 59.49 ± 4.22%, 54.83 ± 4.49%, and 75.73 ± 4.37%, respectively. Molecular analysis showed modulation of angiogenic and inflammatory gene expression. Biochemical assays confirmed improved antioxidant status and reduced lipid peroxidation. Histological evaluation demonstrated enhanced fibroblast infiltration, neovascularization, and collagen deposition, while biomechanical testing indicated improved tensile strength and elasticity of regenerated tissue. Collectively, these findings demonstrate that resveratrol-functionalized ColAM scaffolds provide a multifunctional therapeutic strategy for diabetic wound repair through coordinated regulation of inflammation, oxidative stress, angiogenesis, and tissue remodeling.